文献

J-GLOBAL ID：201902254248815948   整理番号：19A1369294

胃癌に対する抗PD-1抗体療法後の化学療法の有効性と安全性:硬化性胆管炎の症例

Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis

著者 (13件)： Kono Masashi (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Sakurai Toshiharu (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Okamoto Kazuki (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Masaki Shou (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Nagai Tomoyuki (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Komeda Yoriaki (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Kamata Ken (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Minaga Kosuke (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Yamao Kentarou (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Takenaka Mamoru (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Watanabe Tomohiro (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Nishida Naoshi (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan) ,  Kudo Masatoshi (Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan)
資料名： Internal Medicine (Web)  (Internal Medicine (Web))
巻： 58  号： 9  ページ： 1263-1266(J-STAGE)  発行年： 2019年 
JST資料番号： U0033A  ISSN： 1349-7235  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： 日本 (JPN)  言語： 英語 (EN)

抄録/ポイント： ・プログラム細胞死-1(PD-1)シグナル伝達を標的とする免...

シソーラス用語： ヒト ,...
準シソーラス用語： PD-1 ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A1369294&from=J-GLOBAL&jstjournalNo=U0033A") }}

著者キーワード (5件)： ラムコリマブ ,  NAB-パクリタキセル ,  ニボルマブ ,  免疫チェックポイント ,  胆嚢炎

分類 (3件)： 臨床腫よう学一般  (GE03010Y) ,  消化器の腫よう  (GH04000D) ,  抗腫よう薬の臨床への応用  (GW16020L)

引用文献 (23件)：

• 1. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390: 2461-2471, 2017.
• 2. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12: 864-872, 2007.
• 3. Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8: 49, 2017.
• 4. Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology 44: 1063-1074, 2006.
• 5. Kulaksiz H, Heuberger D, Engler S. et al. Poor outcome in progressive sclerosing cholangitis after septic shock. Endoscopy 40: 214-218, 2008.

タイトルに関連する用語 (8件)： 胃癌 ,  抗PD-1抗体 ,  療法 ,  化学療法 ,  有効性 ,  安全性 ,  硬化性胆管炎 ,  症例